21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
21:54 , May 8, 2019 |  BC Extra  |  Clinical News

AZ, Daiichi planning global submissions for breast cancer ADC

After AstraZeneca paid Daiichi $1.35 billion up front to jointly develop and commercialize the Japanese pharma’s trastuzumab deruxtecan (DS-8201), the partners reported Wednesday that the antibody-drug conjugate met the primary endpoint in the pivotal Phase...
22:52 , May 3, 2019 |  BC Extra  |  Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
03:13 , Mar 29, 2019 |  BC Extra  |  Company News

Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal

AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs. Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they...
18:24 , Mar 7, 2019 |  BC Innovations  |  Distillery Therapeutics

mir-515 inhibitor sensitizes HER2-negative breast and liver cancers to Kadcyla, Herceptin

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; liver cancer In vitro and cell culture studies suggest an inhibitor of miR-515 could sensitize HER2-negative breast and liver cancers to anti-HER2 therapies. Chemical synthesis and in vitro testing...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
19:53 , Feb 11, 2019 |  BC Extra  |  Preclinical News

Scripps miRNA flips HER2-negative tumors to HER2-positive

Researchers at the Scripps Research Institute developed a dimeric small molecule that can switch on HER2 in cancers cells where it was previously not up-regulated, sensitizing HER2-negative breast cancer and liver cancer cells to HER2-targeted...
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...